Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

易普利姆玛 医学 无容量 内科学 临床终点 安慰剂 肿瘤科 临床试验 随机对照试验 不利影响 黑色素瘤 临床研究阶段 外科 癌症 免疫疗法 病理 替代医学 癌症研究
作者
F. Stephen Hodi,Jason Chesney,Anna C. Pavlick,Caroline Robert,Kenneth F. Grossmann,David F. McDermott,Gerald P. Linette,Nicolás Meyer,Jeffrey K. Giguere,Sanjiv S. Agarwala,Montaser Shaheen,Marc S. Ernstoff,David R. Minor,Tara C. Gangadhar,Matthew H. Taylor,Patrick A. Ott,Christine E. Horak,Paul Gagnier,Joel Jiang,Jedd D. Wolchok,Michael A. Postow
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:17 (11): 1558-1568 被引量:842
标识
DOI:10.1016/s1470-2045(16)30366-7
摘要

Results from phase 2 and 3 trials in patients with advanced melanoma have shown significant improvements in the proportion of patients achieving an objective response and prolonged progression-free survival with the combination of nivolumab (an anti-PD-1 antibody) plus ipilimumab (an anti-CTLA-4 antibody) compared with ipilimumab alone. We report 2-year overall survival data from a randomised controlled trial assessing this treatment in previously untreated advanced melanoma.In this multicentre, double-blind, randomised, controlled, phase 2 trial (CheckMate 069) we recruited patients from 19 specialist cancer centres in two countries (France and the USA). Eligible patients were aged 18 years or older with previously untreated, unresectable stage III or IV melanoma and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients were randomly assigned 2:1 to receive an intravenous infusion of nivolumab 1 mg/kg plus ipilimumab 3 mg/kg or ipilimumab 3 mg/kg plus placebo, every 3 weeks for four doses. Subsequently, patients assigned to nivolumab plus ipilimumab received nivolumab 3 mg/kg every 2 weeks until disease progression or unacceptable toxicity, whereas patients allocated to ipilimumab alone received placebo every 2 weeks during this phase. Randomisation was done via an interactive voice response system with a permuted block schedule (block size of six) and stratification by BRAF mutation status. The study funder, patients, investigators, and study site staff were masked to treatment assignment. The primary endpoint, which has been reported previously, was the proportion of patients with BRAFV600 wild-type melanoma achieving an investigator-assessed objective response. Overall survival was an exploratory endpoint and is reported in this Article. Efficacy analyses were done on the intention-to-treat population, whereas safety was assessed in all treated patients who received at least one dose of study drug. This study is registered with ClinicalTrials.gov, number NCT01927419, and is ongoing but no longer enrolling patients.Between Sept 16, 2013, and Feb 6, 2014, we screened 179 patients and enrolled 142, randomly assigning 95 patients to nivolumab plus ipilimumab and 47 to ipilimumab alone. In each treatment group, one patient no longer met the study criteria following randomisation and thus did not receive study drug. At a median follow-up of 24·5 months (IQR 9·1-25·7), 2-year overall survival was 63·8% (95% CI 53·3-72·6) for those assigned to nivolumab plus ipilimumab and 53·6% (95% CI 38·1-66·8) for those assigned to ipilimumab alone; median overall survival had not been reached in either group (hazard ratio 0·74, 95% CI 0·43-1·26; p=0·26). Treatment-related grade 3-4 adverse events were reported in 51 (54%) of 94 patients who received nivolumab plus ipilimumab compared with nine (20%) of 46 patients who received ipilimumab alone. The most common treatment-related grade 3-4 adverse events were colitis (12 [13%] of 94 patients) and increased alanine aminotransferase (ten [11%]) in the combination group and diarrhoea (five [11%] of 46 patients) and hypophysitis (two [4%]) in the ipilimumab alone group. Serious grade 3-4 treatment-related adverse events were reported in 34 (36%) of 94 patients who received nivolumab plus ipilimumab (including colitis in ten [11%] of 94 patients, and diarrhoea in five [5%]) compared with four (9%) of 46 patients who received ipilimumab alone (including diarrhoea in two [4%] of 46 patients, colitis in one [2%], and hypophysitis in one [2%]). No new types of treatment-related adverse events or treatment-related deaths occurred in this updated analysis.Although follow-up of the patients in this study is ongoing, the results of this analysis suggest that the combination of first-line nivolumab plus ipilimumab might lead to improved outcomes compared with first-line ipilimumab alone in patients with advanced melanoma. The results suggest encouraging survival outcomes with immunotherapy in this population of patients.Bristol-Myers Squibb.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
mingxi发布了新的文献求助20
刚刚
1024完成签到,获得积分10
1秒前
温白开发布了新的文献求助10
2秒前
WilliamTT发布了新的文献求助10
3秒前
Zino完成签到,获得积分10
4秒前
王小武完成签到,获得积分10
4秒前
CodeCraft的应助被秋天采纳,获得10
5秒前
zz发布了新的文献求助10
5秒前
wilapple完成签到,获得积分10
5秒前
酷酷的辉发布了新的文献求助30
7秒前
加点油完成签到,获得积分10
7秒前
8秒前
9秒前
Hello的应助被9465426采纳,获得30
9秒前
好运莲莲发布了新的文献求助20
9秒前
ding的应助被细心的凡蕾采纳,获得10
10秒前
虾仁不wink发布了新的文献求助10
10秒前
科研通AI6.3的应助被iceanbecky采纳,获得10
12秒前
寒冷犀牛完成签到,获得积分10
12秒前
12秒前
冉冉发布了新的文献求助30
13秒前
优美语梦完成签到 ,获得积分10
15秒前
tina发布了新的文献求助10
16秒前
16秒前
17秒前
YUEYUEHENCHEN发布了新的文献求助10
17秒前
星遨发布了新的文献求助30
19秒前
19秒前
枫叶做的风铃关注了科研通微信公众号
19秒前
19秒前
科目三的应助被fff采纳,获得10
20秒前
20秒前
小杨肉串完成签到,获得积分10
21秒前
YUNshu完成签到 ,获得积分10
21秒前
xi发布了新的文献求助10
22秒前
ww123发布了新的文献求助10
22秒前
今后的应助被hhud采纳,获得10
22秒前
周青春偶像完成签到,获得积分10
24秒前
王宝宝发布了新的文献求助30
26秒前
科研通AI6.3的应助被zzzzz采纳,获得10
27秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8177849
求助须知:如何正确求助?哪些是违规求助? 9568641
关于积分的说明 21800145
捐赠科研通 7772473
什么是DOI,文献DOI怎么找? 3432537
关于科研通互助平台的介绍 2556720
邀请新用户注册赠送积分活动 2478067